Compare Stocks: HBIO, MXCT, QTRX, and NAUT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HBIO Harvard Bioscience	$8.02 +0.3%	$6.63	$3.75 ▼ $9.40	$36.42M	1.53	25,062 shs	9,893 shs
MXCT MaxCyte	$1.28 +1.6%	$1.24	$0.64 ▼ $1.87	$130.04M	1.52	828,667 shs	333,514 shs
NAUT Nautilus Biotechnology	$0.90 -1.6%	$1.28	$0.65 ▼ $4.31	$117.01M	0.87	630,537 shs	575,798 shs
QTRX Quanterix	$2.69 +4.3%	$3.45	$2.15 ▼ $8.77	$122.02M	1.04	920,632 shs	274,588 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HBIO Harvard Bioscience	+0.25%	+1.13%	+25.90%	+29.35%	+69.20%
MXCT MaxCyte	+1.59%	+4.92%	+19.63%	+12.28%	-7.25%
NAUT Nautilus Biotechnology	-1.59%	+2.17%	-2.70%	-62.14%	+41.61%
QTRX Quanterix	+4.26%	+1.89%	-28.46%	-18.48%	-38.16%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HBIO Harvard Bioscience	$8.02 +0.3%	$6.63	$3.75 ▼ $9.40	$36.42M	1.53	25,062 shs	9,893 shs
MXCT MaxCyte	$1.28 +1.6%	$1.24	$0.64 ▼ $1.87	$130.04M	1.52	828,667 shs	333,514 shs
NAUT Nautilus Biotechnology	$0.90 -1.6%	$1.28	$0.65 ▼ $4.31	$117.01M	0.87	630,537 shs	575,798 shs
QTRX Quanterix	$2.69 +4.3%	$3.45	$2.15 ▼ $8.77	$122.02M	1.04	920,632 shs	274,588 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HBIO Harvard Bioscience	+0.25%	+1.13%	+25.90%	+29.35%	+69.20%
MXCT MaxCyte	+1.59%	+4.92%	+19.63%	+12.28%	-7.25%
NAUT Nautilus Biotechnology	-1.59%	+2.17%	-2.70%	-62.14%	+41.61%
QTRX Quanterix	+4.26%	+1.89%	-28.46%	-18.48%	-38.16%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HBIO Harvard Bioscience	2.00	Hold	$6.75	-15.84% Downside
MXCT MaxCyte	2.00	Hold	$5.00	290.63% Upside
NAUT Nautilus Biotechnology	2.00	Hold	$4.00	342.04% Upside
QTRX Quanterix	1.67	Reduce	$3.00	11.52% Upside

Current Analyst Ratings Breakdown

Latest HBIO, MXCT, QTRX, and NAUT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/25/2026	MXCT MaxCyte	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/24/2026	MXCT MaxCyte	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
8/17/2026	QTRX Quanterix	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Hold	$4.00 ➝ $3.00
8/14/2026	HBIO Harvard Bioscience	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/12/2026	HBIO Harvard Bioscience	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Speculative Buy	$6.00 ➝ $7.50
8/11/2026	MXCT MaxCyte	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/11/2026	QTRX Quanterix	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Hold	$4.00 ➝ $3.00
8/7/2026	QTRX Quanterix	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/5/2026	NAUT Nautilus Biotechnology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/28/2026	MXCT MaxCyte	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/17/2026	NAUT Nautilus Biotechnology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 9/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HBIO Harvard Bioscience	$86.55M	0.42	$11.79 per share	0.68	$1.63 per share	4.92
MXCT MaxCyte	$33.03M	4.00	N/A	N/A	$1.54 per share	0.83
NAUT Nautilus Biotechnology	N/A	N/A	N/A	N/A	$1.03 per share	N/A
QTRX Quanterix	$153.17M	0.83	N/A	N/A	$5.02 per share	0.54

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HBIO Harvard Bioscience	-$56.70M	-$2.31	N/A	N/A	N/A	-11.86%	-33.13%	-4.80%	11/5/2026 (Estimated)
MXCT MaxCyte	-$44.63M	-$0.33	N/A	N/A	N/A	-114.77%	-18.92%	-16.14%	11/11/2026 (Estimated)
NAUT Nautilus Biotechnology	-$59M	-$0.45	N/A	N/A	N/A	N/A	-37.58%	-30.83%	10/27/2026 (Estimated)
QTRX Quanterix	-$107.15M	-$2.63	N/A	N/A	N/A	-80.25%	-26.09%	-19.03%	11/9/2026 (Estimated)

Latest HBIO, MXCT, QTRX, and NAUT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	MXCT MaxCyte	-$0.09	-$0.08	+$0.01	-$0.08	$6.51 million	$6.50 million
8/11/2026	Q2 2026	HBIO Harvard Bioscience	-$0.21	-$0.14	+$0.07	-$0.64	$21.45 million	$22.73 million
8/10/2026	Q2 2026	QTRX Quanterix	-$0.4103	-$1.04	-$0.6297	-$1.04	$37.48 million	$32.91 million
7/28/2026	Q2 2026	NAUT Nautilus Biotechnology	-$0.1350	-$0.11	+$0.0250	-$0.11	$0.10 million	$0.19 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
HBIO Harvard Bioscience	N/A	N/A	N/A	N/A	N/A
MXCT MaxCyte	N/A	N/A	N/A	N/A	N/A
NAUT Nautilus Biotechnology	N/A	N/A	N/A	N/A	N/A
QTRX Quanterix	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HBIO Harvard Bioscience	4.94	1.87	0.98
MXCT MaxCyte	N/A	12.26	11.47
NAUT Nautilus Biotechnology	N/A	10.14	10.14
QTRX Quanterix	N/A	3.40	2.45

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HBIO Harvard Bioscience	80.87%
MXCT MaxCyte	68.81%
NAUT Nautilus Biotechnology	50.71%
QTRX Quanterix	86.48%

Insider Ownership

Company	Insider Ownership
HBIO Harvard Bioscience	17.03%
MXCT MaxCyte	4.10%
NAUT Nautilus Biotechnology	41.10%
QTRX Quanterix	1.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HBIO Harvard Bioscience	490	4.55 million	3.78 million	No Data
MXCT MaxCyte	80	103.21 million	98.98 million	Optionable
NAUT Nautilus Biotechnology	130	127.25 million	74.95 million	Optionable
QTRX Quanterix	460	47.29 million	46.58 million	Optionable

HBIO, MXCT, QTRX, and NAUT Headlines

Recent News About These Companies

3,635,411 Shares in Quanterix Corporation $QTRX Bought by BlackRock Inc.

September 4 at 3:20 AM | marketbeat.com

Head to Head Analysis: Azenta (NASDAQ:AZTA) vs. Quanterix (NASDAQ:QTRX)

August 29, 2026 | americanbankingnews.com

Quanterix (QTRX) Q2 2026 Earnings Call Transcript

August 17, 2026 | finance.yahoo.com

Quanterix (NASDAQ:QTRX) Price Target Cut to $3.00 by Analysts at Canaccord Genuity Group

August 17, 2026 | marketbeat.com

GSA Capital Partners LLP Makes New Investment in Quanterix Corporation $QTRX

August 17, 2026 | marketbeat.com

Quanterix Reshapes Sales Strategy, Targets Q4 FDA Decision for Alzheimer’s Blood Test

August 16, 2026 | marketbeat.com

Quanterix Corporation

August 16, 2026 | edition.cnn.com

Quanterix (NASDAQ:QTRX) Lowered to Sell Rating by Wall Street Zen

August 15, 2026 | marketbeat.com

TD Cowen Issues Pessimistic Forecast for Quanterix (NASDAQ:QTRX) Stock Price

August 11, 2026 | marketbeat.com

Quanterix Corp (QTRX) (Q2 2026) Earnings Call Highlights: Revenue Miss and Guidance Cut Amid ...

August 10, 2026 | finance.yahoo.com

Quanterix Q2 Earnings Call Highlights

August 10, 2026 | marketbeat.com

Quanterix (NASDAQ:QTRX) Announces Quarterly Earnings Results

August 10, 2026 | marketbeat.com

Quanterix Names Jim Gute Chief Commercial Officer

August 10, 2026 | businesswire.com

Quanterix To Participate in Canaccord Genuity Capital Markets 46th Annual Growth Conference on August 11-12

August 6, 2026 | aol.comA

Quanterix To Report Second Quarter 2026 Financial Results on August 10, 2026

August 4, 2026 | lasvegassun.comL

Quanterix: Trading Below 1x Sales Despite A Changing Story

July 20, 2026 | seekingalpha.com

Quanterix Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

July 16, 2026 | businesswire.com

Quanterix rises on coverage win for Alzheimer’s test

July 15, 2026 | seekingalpha.com

Anthem Blue Cross and Blue Shield Establishes Commercial Coverage for LucentAD® Complete; Quanterix to Present New Data Highlighting Multi-Analyte Advantages

July 14, 2026 | businesswire.com

Quanterix (QTRX) Stock Fair Value Falls After Analysts Cut Price Targets

July 9, 2026 | finance.yahoo.com

Quanterix stock is popping in pre-market: Here's why

June 24, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

HBIO, MXCT, QTRX, and NAUT Company Descriptions

Harvard Bioscience NASDAQ:HBIO

$8.02 +0.02 (+0.25%)

As of 09/4/2026 04:00 PM Eastern

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.

MaxCyte NASDAQ:MXCT

$1.28 +0.02 (+1.59%)

As of 09/4/2026 04:00 PM Eastern

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

Nautilus Biotechnology NASDAQ:NAUT

$0.90 -0.01 (-1.59%)

As of 09/4/2026 04:00 PM Eastern

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Quanterix NASDAQ:QTRX

$2.69 +0.11 (+4.26%)

As of 09/4/2026 04:00 PM Eastern

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HBIO, MXCT, QTRX, and NAUT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HBIO, MXCT, QTRX, and NAUT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HBIO, MXCT, QTRX, and NAUT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

HBIO, MXCT, QTRX, and NAUT Company Descriptions

Harvard Bioscience NASDAQ:HBIO

MaxCyte NASDAQ:MXCT

Nautilus Biotechnology NASDAQ:NAUT

Quanterix NASDAQ:QTRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HBIO, MXCT, QTRX, and NAUT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HBIO, MXCT, QTRX, and NAUT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HBIO, MXCT, QTRX, and NAUT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

HBIO, MXCT, QTRX, and NAUT Company Descriptions

Harvard Bioscience NASDAQ:HBIO

MaxCyte NASDAQ:MXCT

Nautilus Biotechnology NASDAQ:NAUT

Quanterix NASDAQ:QTRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools